以色列:接种两剂辉瑞/BioNTech疫苗後风险下降95.8%
以色列截至上月底已为约170万人接种第二剂辉瑞/BioNTech疫苗,当地卫生部指出,接种第二剂疫苗後,感染新型冠状病毒的风险下降95.8%,疫苗预防发烧或呼吸困难有效率为98%,预防住院和死亡方面有效率则为98.9%。
以色列总理内塔尼亚胡表示,可允许接种疫苗的国民参与各项体育文化活动、前往健身房及游泳池,已接种两剂疫苗的人将能够在未来几天下载「绿色通行证」,预计在未来两周内让95%的50岁以上国民接种疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.